Pharma IQ Glossary: Adverse Drug Reaction (ADR)
Adverse Drug Reaction (ADR) is an expression that describes harm associated with the use of given medications at a normal dose. Adverse events can range from mild to severe. Serious adverse drug reactions are those that can cause disability, are life-threatening, result in hospitalization or death, or are birth defects.
5 Challenges that Continue to Plague the $2 Billion Pharmacovigilance Sector
May 08 by Pharma IQThe Asia Pacific region is fast becoming the growth center of the worldwide pharmaceuticals market. By 2015, these markets are projected to account for almost a third of the total pharmaceutical sales...
Saudi FDA: Working with Industry to Improve the Reporting of Adverse Reactions
December 13 by Andrea CharlesIn this interview Dr. Nasser Al-Qahtani, Head, Adverse Drug Reactions Evaluation Department Saudi FDA speaks to Andrea Charles from Pharma IQ, about the Saudi FDA pharmacovigilance system and wha...
Pharmacoepidemiology and Pharmacovigilance
July 04 by Elie MagdalaniPharmacology is the study of the effects of drugs. The other interesting branch known as the “clinical pharmacology” is interested in the effects of drugs in humans by which therapy is individualised...
Embracing Pharmacovigilance with Technology
May 18 by Pharma IQMany companies in the pharmaceutical industry have provisions in place to deal with pharmacovigilance and other so-called late phase issues, as they realise the important role they can play in boosti...
Global Drug Safety and Risk Management
May 06 by Elie MagdalaniReported adverse events are an important tool for implementing a risk management program. An important contributing factor in the evolved AEs the condition of chronically ill patients taking a drug da...
Pharmacovigilance is Not Just About Compliance
March 23 by Andrea CharlesDr. Viraj Suvarna, Medical Director and Head of Medical Affairs at Boehringer Ingelheim, joins Andrea Charles from Pharma IQ to discuss the importance of training and re-training field operatives to r...
Building a Harmonised Pharmacovigilance Framework in Asia
March 23 by Pharma IQBy the end of 2011 China's pharmaceutical market will be the third largest in the world, contributing more than $40 billion (£25 billion) in annual sales by 2013, according to analysis from IMS Health...
Thinking Patients’ Health, for a Safe Medicine
December 17 by Elie Magdalani“To undergo treatment you have to be very healthy, because apart from your sickness you have to withstand the medicine”. Molière (French Dramatist, 1622-1673) Although Molière was not a health care p...
Multiparticulate Drug Delivery Systems
October 03 by T. E. Gopala Krishna MurthyMultiparticulates are the discrete, small, repetitive units of drug particles which may or may not possess similar drug release pattern.
Would ASEAN Accept Data and Reviews that Cross Borders?
August 11 by Bryan CamoensRobert Lim, Head of Haematology and Oncology, for the National University Cancer Institute, speaks exclusively to Bryan Camoens from Pharma IQ, on the fundamental difference between pharmacodili...
Applying Biopharmaceutical Nanotechnology to Diagnostics, Drug Discovery and Drug Delivery
August 11 by Pharma IQThe application of nanobiotechnology has far ranging uses within a number of sectors of the life sciences industry, including drug discovery, formulation, clinical assessment, drug delivery and monito...
Pharmacovigilance in Asia: Will China One Day Take the Lead?
July 29 by Bryan CamoensJean Christophe Delumeau, Head of Pharmacovigilance Asia-Pacific for Bayer Healthcare Global R&D Centre, speaks exclusively to Bryan Camoens from Pharma IQ, on the evolution of Pharmacovigilance...
